Table 2.
Characteristics of patients with early-stage cervical cancer under follow-up based on their COVID-19 status.
| Characteristics * | SARS-CoV-2 Negative (n = 128) | SARS-CoV-2 Positive (n = 32) | p-Value |
|---|---|---|---|
| Age, years | 38.0 ± 9.4 | 39.2 ± 9.1 | 0.516 |
| BMI, kg/m2 | 26.4 ± 3.5 | 27.8 ± 4.4 | 0.057 |
| Overall survival | 108 (84.4%) | 28 (87.5%) | 0.657 |
| DFS **, months, (median[IQR]) | 34 [31–36] | 33 [30–36] | 0.531 |
| Follow-up, months, (median[IQR]) | 34 [28–36] | 34 [29–36] | 0.948 |
| Surgical treatment type | 0.076 | ||
| Robot surgery | 16 (12.5%) | 8 (25.0%) | |
| Open surgery | 112 (87.5%) | 24 (75.0%) | |
| Tumor size | 0.871 | ||
| <2 cm | 50 (39.1%) | 12 (37.5%) | |
| ≥2 cm | 78 (60.9%) | 20 (62.5%) | |
| Lymph node involvement | 0.141 | ||
| 0 | 94 (73.4%) | 18 (56.3%) | |
| 1 | 12 (9.4%) | 6 (18.7%) | |
| >1 | 22 (17.2%) | 8 (25.0%) | |
| FIGO stage | 0.490 | ||
| IA2 | 40 (31.3%) | 8 (25.0%) | |
| IB1 | 88 (68.7%) | 24 (75.0%) | |
| Differentiation grade | 0.967 | ||
| Grade 1 | 74 (57.8%) | 18 (56.3%) | |
| Grade 2 | 40 (31.2%) | 10 (31.3%) | |
| Grade 3 | 14 (11.0%) | 4 (12.4%) | |
| Relapse (n = 38) | 0.868 | ||
| Local | 16 (12.4%) | 3 (9.4%) | |
| Regional | 8 (6.3%) | 2 (6.3%) | |
| Distant | 8 (6.3%) | 1 (3.2%) | |
| Total | 32 (25.0%) | 6 (18.8%) | |
| Histology | 0.223 | ||
| Squamous-cell | 111 (86.7%) | 25 (78.1%) | |
| Adenocarcinoma | 17 (13.3%) | 7 (21.9%) | |
| Adjuvant treatment | 0.762 | ||
| Radiotherapy-only | 20 (15.6%) | 8 (25.0%) | |
| Chemotherapy-only | 5 (3.9%) | 3 (9.4%) | |
| Radio-chemotherapy | 6 (4.7%) | 4 (12.4%) | |
| Clavien-Dindo scale | Classic surgery | Robotic surgery | 0.031 |
| No complications | 45 (35.2%) | 20 (62.5%) | |
| Score 1 | 52 (40.6%) | 8 (25.0%) | |
| Score 2 | 24 (18.8%) | 2 (6.25%) | |
| Score 3 | 7 (5.4%) | 2 (6.25%) |
* Data reported as n(%) unless specified differently; ** DFS—Disease-Free Survival.